Celcuity Inc. (CELC): Price and Financial Metrics
CELC Price/Volume Stats
| Current price | $17.24 | 52-week high | $22.19 |
| Prev. close | $17.54 | 52-week low | $8.39 |
| Day low | $17.18 | Volume | 90,600 |
| Day high | $18.21 | Avg. volume | 216,529 |
| 50-day MA | $17.59 | Dividend yield | N/A |
| 200-day MA | $13.16 | Market Cap | 525.01M |
CELC Stock Price Chart Interactive Chart >
Celcuity Inc. (CELC) Company Bio
Celcuity LLC, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. It develops CELx tests to diagnose breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is based in Minneapolis, Minnesota.
Latest CELC News From Around the Web
Below are the latest news stories about CELCUITY INC that investors may wish to consider to help them evaluate CELC as an investment opportunity.
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer SymposiumMINNEAPOLIS, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today presented data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR (PAM) inhibitors in breast cancer cell lines during a poster session at the 2023 San Antonio Breast Cancer Symposium (SABCS). The preclinical studies evaluated gedatolisib, a pan-PI3K/mTOR inhibitor, and PAM inhibitors that selectivel |
Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer SymposiumMINNEAPOLIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract accepted for a poster presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS) is now available on the SABCS website. The 2023 San Antonio Breast Cancer Symposium (SABCS) is being held virtually and in-person from December 5-9, 2023. The presentation will include potency and effica |
Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx ConferenceMINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the 6th Annual Evercore ISI HealthCONx Conference held in Miami. Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, is scheduled for a fireside chat at 12:30 p.m. ET on Wednesday, November 29, 2023. A live webcast of the event will be available using this weblin |
Celcuity Inc. (NASDAQ:CELC) Q3 2023 Earnings Call TranscriptCelcuity Inc. (NASDAQ:CELC) Q3 2023 Earnings Call Transcript November 13, 2023 Operator: Greetings, and welcome to the Celcuity Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It […] |
Q3 2023 Celcuity Inc Earnings CallQ3 2023 Celcuity Inc Earnings Call |
CELC Price Returns
| 1-mo | -3.15% |
| 3-mo | 17.76% |
| 6-mo | 74.49% |
| 1-year | 81.66% |
| 3-year | -31.91% |
| 5-year | -20.22% |
| YTD | 18.33% |
| 2023 | 4.00% |
| 2022 | 6.22% |
| 2021 | 44.00% |
| 2020 | -13.91% |
| 2019 | -55.65% |
Loading social stream, please wait...